Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
forging connections all over the world, we work together to develop solutions for the global challenges of today and tomorrow. Where to apply Website https://academicpositions.com/ad/eth-zurich/2026
-
: https://www.epfl.ch/labs/hobel/ For more information about Prof. Dusan Licina: https://people.epfl.ch/dusan.licina For more information about EPFL: https://www.epfl.ch/en/ For more information about Smart
-
portal. Applications by e-mail and by post will not be considered. Where to apply Website https://academicpositions.com/ad/empa/2026/postdoc-position-on-redox-targeted-f… Requirements Research
-
Foster ([email protected]) - https://laser.epfl.ch/ Contract Start Date : 01.12.2026, or to be determined Activity Rate : 100.00 Contract Type: CDD Duration: 1 year, renewable Reference: 2464
-
, cell biology and gas-exchange physiology. Within the research unit “Cereal Stem Cell Systems - RU52350; https://cerealstemcells.de ”, we are recruiting a Postdoc to investigate how grass leaves spatially
-
the earth sciences. NCCR Genesis does not aim to provide answers in all fields, but to drive innovative research and achieve decisive progress. Details on NCCR Genesis are available on its website https
-
, diabetes and cancer; see https://data.snf.ch/grants/grant/189065 ii) developing and validation of novel chemical probes and degraders to dissect mechanisms of adverse effects in cancer and metabolism. For a
-
than 18,500 people, including over 14,000 students and 4,000 researchers from more than 120 different countries. Postdoc in ML-Based Co-Design at EPFL Mission The EPFL computer vision lab (https://www.epfl.ch
-
positions. https://www.epfl.ch/labs/entc/ Education You will work closely with Dr. Davide Bavato, head of EPFL’s recently established Entrepreneurship Education Hub. The Hub is developing a structured
-
protocols. In close collaboration with the lab of George Coukos (https://agora-cancer.ch/laboratory/coukos-lab/ ), we will derive protocols enabling rapid expansion of cancer-specific, autologous TILs